256 related articles for article (PubMed ID: 37147645)
21. Large Scale, Multicenter, Prospective Study of Apatinib in Advanced Gastric Cancer: A Real-World Study from China.
Peng W; Zhang F; Wang Z; Li D; He Y; Ning Z; Sheng L; Wang J; Xia X; Yu C; Wang Z; Zhao Y; Liang H; Hu B; Sun C; Wang D; Cheng Y; Pan M; Xia L; Guo X; Zhang Y; Hu Z; Li X; Lu L; Zhang J; Qian H; Xie H; Sun G
Cancer Manag Res; 2020; 12():6977-6985. PubMed ID: 32821164
[TBL] [Abstract][Full Text] [Related]
22. Pertuzumab in combination with trastuzumab and chemotherapy for Chinese patients with HER2-positive metastatic gastric or gastroesophageal junction cancer: a subpopulation analysis of the JACOB trial.
Liu T; Qin Y; Li J; Xu R; Xu J; Yang S; Qin S; Bai Y; Wu C; Mao Y; Wu H; Ge Y; Shen L
Cancer Commun (Lond); 2019 Jun; 39(1):38. PubMed ID: 31234927
[TBL] [Abstract][Full Text] [Related]
23. Safety and Efficacy of Apatinib Monotherapy for Unresectable, Metastatic Esophageal Cancer: A Single-Arm, Open-Label, Phase II Study.
Yanwei L; Feng H; Ren P; Yue J; Zhang W; Tang P; Shang X; Pang Q; Liu D; Chen C; Pan Z; Tao YZ
Oncologist; 2020 Oct; 25(10):e1464-e1472. PubMed ID: 32342599
[TBL] [Abstract][Full Text] [Related]
24. Effectiveness and safety of low-dose apatinib in advanced gastric cancer: A real-world study.
Du Y; Cao Q; Jiang C; Liang H; Ning Z; Ji C; Wang J; Zhou C; Jiang Z; Yu C; Li L; Zhao Y; Xu Y; Xu T; Hu W; Wang D; Cheng H; Wang G; Zhou J; Wang S; Zhang Y; Hu Z; Li X; Lu D; Zhang J; Xie H; Sun G
Cancer Med; 2020 Jul; 9(14):5008-5014. PubMed ID: 32441892
[TBL] [Abstract][Full Text] [Related]
25. First-line panitumumab plus docetaxel and cisplatin in advanced gastric and gastro-oesophageal junction adenocarcinoma: results of a phase II trial.
Quintero Aldana G; Salgado M; Candamio S; Méndez JC; Jorge M; Reboredo M; Vázquez Tuñas L; Romero C; Covela M; Fernández Montes A; Carmona M; Vidal Insua Y; López R;
Clin Transl Oncol; 2020 Apr; 22(4):495-502. PubMed ID: 31280434
[TBL] [Abstract][Full Text] [Related]
26. Safety and efficacy of pembrolizumab in combination with S-1 plus oxaliplatin as a first-line treatment in patients with advanced gastric/gastroesophageal junction cancer: Cohort 1 data from the KEYNOTE-659 phase IIb study.
Kawazoe A; Yamaguchi K; Yasui H; Negoro Y; Azuma M; Amagai K; Hara H; Baba H; Tsuda M; Hosaka H; Kawakami H; Oshima T; Omuro Y; Machida N; Esaki T; Yoshida K; Nishina T; Komatsu Y; Han SR; Shiratori S; Shitara K
Eur J Cancer; 2020 Apr; 129():97-106. PubMed ID: 32145474
[TBL] [Abstract][Full Text] [Related]
27. Efficacy and safety for Apatinib treatment in advanced gastric cancer: a real world study.
Zhang Y; Han C; Li J; Zhang L; Wang L; Ye S; Hu Y; Bai L
Sci Rep; 2017 Oct; 7(1):13208. PubMed ID: 29038432
[TBL] [Abstract][Full Text] [Related]
28. Efficacy and safety of a novel anti-HER2 therapeutic antibody RC48 in patients with HER2-overexpressing, locally advanced or metastatic gastric or gastroesophageal junction cancer: a single-arm phase II study.
Peng Z; Liu T; Wei J; Wang A; He Y; Yang L; Zhang X; Fan N; Luo S; Li Z; Gu K; Lu J; Xu J; Fan Q; Xu R; Zhang L; Li E; Sun Y; Yu G; Bai C; Liu Y; Zeng J; Ying J; Liang X; Xu N; Gao C; Shu Y; Ma D; Dai G; Li S; Deng T; Cui Y; Fang J; Ba Y; Shen L
Cancer Commun (Lond); 2021 Nov; 41(11):1173-1182. PubMed ID: 34665942
[TBL] [Abstract][Full Text] [Related]
29. Ramucirumab plus pembrolizumab in patients with previously treated advanced non-small-cell lung cancer, gastro-oesophageal cancer, or urothelial carcinomas (JVDF): a multicohort, non-randomised, open-label, phase 1a/b trial.
Herbst RS; Arkenau HT; Santana-Davila R; Calvo E; Paz-Ares L; Cassier PA; Bendell J; Penel N; Krebs MG; Martin-Liberal J; Isambert N; Soriano A; Wermke M; Cultrera J; Gao L; Widau RC; Mi G; Jin J; Ferry D; Fuchs CS; Petrylak DP; Chau I
Lancet Oncol; 2019 Aug; 20(8):1109-1123. PubMed ID: 31301962
[TBL] [Abstract][Full Text] [Related]
30. Avelumab (anti-PD-L1) as first-line switch-maintenance or second-line therapy in patients with advanced gastric or gastroesophageal junction cancer: phase 1b results from the JAVELIN Solid Tumor trial.
Chung HC; Arkenau HT; Lee J; Rha SY; Oh DY; Wyrwicz L; Kang YK; Lee KW; Infante JR; Lee SS; Kemeny M; Keilholz U; Melichar B; Mita A; Plummer R; Smith D; Gelb AB; Xiong H; Hong J; Chand V; Safran H
J Immunother Cancer; 2019 Feb; 7(1):30. PubMed ID: 30717797
[TBL] [Abstract][Full Text] [Related]
31. Phase II clinical trial using camrelizumab combined with apatinib and chemotherapy as the first-line treatment of advanced esophageal squamous cell carcinoma.
Zhang B; Qi L; Wang X; Xu J; Liu Y; Mu L; Wang X; Bai L; Huang J
Cancer Commun (Lond); 2020 Dec; 40(12):711-720. PubMed ID: 33314747
[TBL] [Abstract][Full Text] [Related]
32. Apatinib vs Placebo in Patients With Locally Advanced or Metastatic, Radioactive Iodine-Refractory Differentiated Thyroid Cancer: The REALITY Randomized Clinical Trial.
Lin Y; Qin S; Li Z; Yang H; Fu W; Li S; Chen W; Gao Z; Miao W; Xu H; Zhang Q; Zhao X; Bao J; Li L; Ren Y; Lin C; Jing S; Ma Q; Liang J; Chen G; Zhang H; Zhang Y; Zhou X; Sang Y; Hou Z
JAMA Oncol; 2022 Feb; 8(2):242-250. PubMed ID: 34913959
[TBL] [Abstract][Full Text] [Related]
33. Apatinib in patients with recurrent or metastatic thymic epithelial tumor: a single-arm, multicenter, open-label, phase II trial.
Song Z; Lou G; Wang Y; Yang Z; Wang W; Ji Y; Chen S; Xu C; Hu X; Zhang Y
BMC Med; 2022 May; 20(1):154. PubMed ID: 35534877
[TBL] [Abstract][Full Text] [Related]
34. Apatinib for patients with metastatic biliary tract carcinoma refractory to standard chemotherapy: results from an investigator-initiated, open-label, single-arm, exploratory phase II study.
Wang C; Huang M; Geng Q; Li W; Chang J; Tang W; Guo W
Ther Adv Med Oncol; 2021; 13():17588359211039047. PubMed ID: 34484431
[TBL] [Abstract][Full Text] [Related]
35. Neoadjuvant apatinib combined with oxaliplatin and capecitabine in patients with locally advanced adenocarcinoma of stomach or gastroesophageal junction: a single-arm, open-label, phase 2 trial.
Tang Z; Wang Y; Yu Y; Cui Y; Liang L; Xu C; Shen Z; Shen K; Wang X; Liu T; Sun Y
BMC Med; 2022 Apr; 20(1):107. PubMed ID: 35382819
[TBL] [Abstract][Full Text] [Related]
36. Rilotumumab in combination with epirubicin, cisplatin, and capecitabine as first-line treatment for gastric or oesophagogastric junction adenocarcinoma: an open-label, dose de-escalation phase 1b study and a double-blind, randomised phase 2 study.
Iveson T; Donehower RC; Davidenko I; Tjulandin S; Deptala A; Harrison M; Nirni S; Lakshmaiah K; Thomas A; Jiang Y; Zhu M; Tang R; Anderson A; Dubey S; Oliner KS; Loh E
Lancet Oncol; 2014 Aug; 15(9):1007-18. PubMed ID: 24965569
[TBL] [Abstract][Full Text] [Related]
37. Efficacy and Safety of Apatinib Treatment for Advanced Cholangiocarcinoma After Failed Gemcitabine-Based Chemotherapy: An Open-Label Phase II Prospective Study.
Zhang G; Gong S; Pang L; Hou L; He W
Front Oncol; 2021; 11():659217. PubMed ID: 34012920
[TBL] [Abstract][Full Text] [Related]
38. Feasibility and Tolerance of Apatinib plus PD-1 Inhibitors for Previously Treated Advanced Gastric Cancer: A Real-World Exploratory Study.
Li LH; Chen WC; Wu G
Dis Markers; 2022; 2022():4322404. PubMed ID: 35531474
[TBL] [Abstract][Full Text] [Related]
39. Multicenter phase II study of apatinib in non-triple-negative metastatic breast cancer.
Hu X; Cao J; Hu W; Wu C; Pan Y; Cai L; Tong Z; Wang S; Li J; Wang Z; Wang B; Chen X; Yu H
BMC Cancer; 2014 Nov; 14():820. PubMed ID: 25376790
[TBL] [Abstract][Full Text] [Related]
40. A Randomized Phase II Study of FOLFOX With or Without the MET Inhibitor Onartuzumab in Advanced Adenocarcinoma of the Stomach and Gastroesophageal Junction.
Shah MA; Cho JY; Tan IB; Tebbutt NC; Yen CJ; Kang A; Shames DS; Bu L; Kang YK
Oncologist; 2016 Sep; 21(9):1085-90. PubMed ID: 27401892
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]